Multi-omics profiling unravel the immune landscape diversity by prognostic signatures of immunotherapy response in triple-negative breast cancer
We developed and validated an immune-related signature for predicting TNBC outcomes and immunotherapy response. This signature reflects underlying immune landscape heterogeneity and provides a crucial method for patient stratification and immunotherapeutic planning.
Authors
- Chunyan Dong (ORCID: https://orcid.org/0000-0003-2392-3185)
- Ziting Zhang
- Zheng Gong (ORCID: https://orcid.org/0000-0001-9789-0596)
- Qi Li (ORCID: https://orcid.org/0000-0001-8776-8730)
- Rong Chai (ORCID: https://orcid.org/0000-0002-6816-6416)
Institutions
- Shanghai East Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.3389/fimmu.2025.1735893
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00